Oklahoma C. difficile Vaccine Development
Oklahoma C. difficile U19 Challenge Core
This project aims to create a better vaccine for C. difficile infections by understanding how current vaccines might not fully protect people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11134711 on NIH RePORTER |
What this research studies
This project focuses on developing a more effective second-generation vaccine for C. difficile, a serious bacterial infection. Researchers are using carefully designed animal models, like mice and hamsters, to test how well different vaccine approaches work. By standardizing these animal tests, the team can reliably compare various vaccine candidates and learn why some might be more protective than others. This foundational work is crucial for moving new vaccine ideas closer to human use.
Who could benefit from this research
Good fit: Patients who are at risk for or have experienced C. difficile infections could potentially benefit from future vaccines developed through this research.
Not a fit: Patients will not receive direct benefit from this foundational animal model research, as it does not involve human subjects or clinical trials.
Why it matters
Potential benefit: If successful, this work could lead to a new, more effective vaccine to prevent C. difficile infections in people.
How similar studies have performed: This project builds upon existing experience with murine and hamster challenge models, suggesting prior foundational work in this area.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Ballard, Jimmy D. — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Ballard, Jimmy D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.